Philippe Bégin, AAAAI 2021: Epicutaneous Immunotherapy for Peanut Allergy
We were delighted to catch up with Philippe Bégin (CHU Sainte-Justine, Montréal, Canada) to discuss the use of epicutaneous immunotherapy for peanut allergy.
The abstract entitled ‘Reduction in Severity Following 12 Months of Epicutaneous Immunotherapy for Peanut Allergy‘ (ABSTRACT NUMBER: 342) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
- What are the pros and cons of oral immunotherapy and epicutaneous immunotherapy for peanut allergy? (0:13)
- Could you give us a brief overview of the clinical development of epicutaneous immunotherapy for peanut allergy? (3:37)
- What are the future directions of immunotherapy for peanut allergy? (4:41)
Disclosures: Philippe Bégin is the clinical trial investigator for DBV technology products.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
Share this Video
Related Videos In Allergic Conditions
William R. Lumry, AAAAI 2023: Lanadelumab for paediatric patients aged 2 to <12 years with hereditary angioedema – the SPRING Study
The SPRING Study (NCT04070326) was a phase 3 study that investigated the safety, pharmacokinetics, and pharmacodynamics of lanadelumab for prevention of hereditary angioedema (HAE) attacks in children. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the aims, design and findings from the SPRING Study and how […]
William R. Lumry, AAAAI 2023: Current treatment paradigm and unmet needs in hereditary angioedema
Hereditary angioedema (HAE) is a rare genetic disease that reduces C1 inhibitor levels and impacts the regulation of several pathways involved in dilation of the blood vessels and results in recurrent episodes of severe swelling. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the unmet needs […]
Ralph Mösges, AAAAI 2023: Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergy
Mannan conjugated birch pollen allergoids are an immunotherapy currently under clinical investigation for the treatment of birch pollen allergy. touchIMMUNOLOGY caught up with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) to discuss the rationale and methodology of the the clinical trial programme for Mannan conjugated birch pollen allergoids, the efficacy and safety findings so […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!